This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Opinion: Discussing the potential of CymaBay's Seladelpar, an investigational drug currently in development for the treatment of patients with PBC

Ticker(s): CBAY

Who's the expert?

Institution: The lowa Clinic

  • General gastroenterologist working in the Midwest at a large multi clinic practice that is independently owned. 
  • Sees a variety of Gl conditions including significant inflammatory bowel disease, significant liver disease, IBS, and others.
  •  Participated in market research surveys and interviews for many years

Interview Goal
This interview will focus on CymaBay's new findings from the phase 3 ENHANCE study regarding the correlation of Seledepar and alleviation of pruritus and reduction of serum IL-31 levels.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.